PURPOSE: To evaluate the efficacy and @entity137 of intravenous @entity1206 as single-agent chemotherapy in @entity1 with advanced or recurrent @entity957 . @entity1 AND METHODS: Between August 1993 and July 1995, 35 @entity1 with advanced or recurrent @entity957 were entered onto this study. @entity1 had received no prior therapeutic chemotherapy. The initial dose of @entity1206 30 mg/m2 was administered as a weekly intravenous infusion. Subsequent doses were unchanged, reduced, escalated, or omitted according to observed @entity137 . @entity1 were evaluated for response and @entity137 using standard Gynecologic Oncology Group (GOG) and World Health Organization criteria, respectively. RESULTS: Thirty-three of 35 @entity1 were assessable for response and 35 of 35 for @entity137 . The overall response rate was 18% (one complete response [CR], five partial responses [PR]). The mean response duration was 5.2 months and the median survival from treatment for all @entity1 was 11.0 months. The major @entity137 was @entity1431 , with 61% of @entity1 who had grade 3 or 4. Gastrointestinal and @entity2359 were infrequent and mild. CONCLUSION: @entity1206 has moderate activity in advanced or recurrent @entity957 . Further studies of combination regimens with this agent are justified in this @entity1 population.

Phase II study of XXXX in advanced and recurrent @entity957 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma of the cervix'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine', 'Vinorelbine'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']
@entity1206 :: (MESH:C030852,Chemical) :: ['vinorelbine']
